As a member of the AstraZeneca Group, Gracell Biotechnologies is a global clinical-stage biopharmaceutical company dedicated to discovering and developing novel autologous and allogeneic cell therapies for cancer and autoimmune diseases. Since its inception, Gracell has established a solid inhouse R&D system. Leveraging its proprietary FasTCAR and TruUCAR technology platforms and SMART CART™ technology modules, Gracell is researching new ways to address current challenges with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal T cell quality and barriers that limit their activity in solid tumors and autoimmune diseases.
Company Details
- Employees
- 39
- Founded
- -
- Address
- Shanghai, Shanghai, Cn
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.gracellbio.com/
- Keywords
- CAR-T and Cell Therapy.
- HQ
- Shanghai, Shanghai
Gracell Biotechnologies Questions
Gracell Biotechnologies's website is https://www.gracellbio.com/
Gracell Biotechnologies's LinkedIn profile is https://www.linkedin.com/company/gracellbio
Gracell Biotechnologies has
39 employees.
View email and phone details for 39
employees at Gracell Biotechnologies.
Gracell Biotechnologies's industry is
Biotechnology Research
Gracell Biotechnologies's top competitors are
Cellectis,
Abelzeta,
Esobiotec,
Astrazeneca,
Capstan Therapeutics,
Poseida Therapeutics, Inc.,
Allogene Therapeutics,
Neogene Therapeutics,
Vyriad,
Fusion Pharmaceuticals.
Gracell Biotechnologies's categories are Biotechnology Research
Gracell Biotechnologies's founding year is 2017
